董事会进一步宣布，经考虑审核委员会的推荐建议后，董事会决议批准委任富睿玛泽为公司新任核数 师，以填补毕马威辞任后产生的临时空缺，自2025年10月24日起生效，并将任职至公司下届股东周年大 会结束为止。根 格隆汇10月24日丨嘉创地产(02421.HK)宣布，毕马威已辞任公司核数师，自2025年10月24日起生效，原 因为公司与毕马威未能就审核集团截至2026年3月31日止财政年度的综合财务报表的审计费用达成共 识。 ...

格隆汇10月24日丨深圳控股(00604.HK)公布，于2025年10月24日，深圳泰运通(公司间接非全资附属公 司)与其股东(即深业泰然及深圳地铁置业)订立贷款协议，据此，深圳泰运通同意按照深业泰然及深圳地 铁置业于深圳泰运通所持股权比例，并根据相同的条款及条件向彼等提供贷款。 将由深圳泰运通向深业泰然及深圳地铁置业提供的贷款合共本金金额分别为人民币12.903亿元及人民币 12.397亿元。贷款融资的期限应为自第一批贷款发放日起计36个月。在此期间，贷款方可根据借款方的 资金要求，以一批或多批的方式发放贷款。贷款按单利固定年利率0.05%计息，于整个贷款期间保持不 变。日利率须将年利率除以360计算。 据悉，深圳泰运通为主要从事发展及建设位于深圳的一个住宅项目的项目公司。该项目已完成且深圳泰 运通已于项目中产生盈余现金。由于深圳泰运通并无重大资本需求，通过向其股东按各自股权比例提供 贷款(所有贷款均以深圳泰运通内部闲置资源拨付)，深圳泰运通能够更有效地利用盈余现金，并让其股 东(包括作为股东之一的集团)从其回笼现金。因此，订约方在厘定贷款协议项下的利率时已参考现行市 场储蓄利率，且贷款协议之条款乃由订约方 ...

Group 1 - The company, Fangzheng Holdings (00418.HK), announced a share buyback on October 24, 2025, costing HKD 115,500 [1] - A total of 154,000 shares will be repurchased at a price of HKD 0.75 per share [1]

龙记集团(00255)发布公告，于2025年10月24日，根据采纳的购股权计划行使购股权发行合共71万股。 ...

Core Viewpoint - Junzhi Group (01300) announced a share buyback of 1.046 million shares at a cost of HKD 329,340 on October 24, 2025 [1] Group 1 - The company executed a buyback program, indicating a strategy to enhance shareholder value [1] - The total expenditure for the buyback was HKD 329,340, reflecting the company's commitment to returning capital to shareholders [1] - The number of shares repurchased was 1.046 million, which may influence the company's stock liquidity and market perception [1]

启明医疗-B(02500)发布公告，近日，公司经导管介入瓣膜置换创新系统Cardiovalve欧洲确证性临床研 究顺利完成全部150例经导管三尖瓣置换(TTVR)患者入组。这是Cardiovalve在三尖瓣反流治疗领域的又 一次重大研发进展，标志着其在获得CE MDR的道路上迈出了重要里程碑。 董事会深信，Cardiovalve完成欧洲确证性临床试验全部患者入组，是其上市进程的重大里程碑，也是全 球三尖瓣反流创新疗法的重大进展。凭借公司在全球结构性心脏病领域建立的研发、生产及商业化的优 势，公司将持续积极推进包括Cardiovalve在内的创新产品的全球临床註册开发进程，将有竞争力的产品 早日获批，使得更多患者获益及实现公司的国际化战略。 Cardiovalve是一款自主研发、同时可用于治疗二尖瓣反流和三尖瓣反流的经导管介入置换产品。与同类 产品相比，Cardiovalve经股静脉的入路方式显著提升了治疗安全性，产品最大55mm的大瓣环设计适用 约95%的患者群体，同时，其独特的短瓣架设计可有效降低心室流出道梗阻风险。Cardiovalve操作简 单、安全、可复制性强，只需定位、锚定、释放三个步骤完成。 TA ...

Group 1: Economic Environment - The Federal Reserve is expected to resume interest rate cuts in Q3 2025, amidst a complex global economic landscape [1] - China continues to implement targeted macro policies, leading to steady economic progress despite facing multiple internal and external risks [1] Group 2: Real Estate Market - The real estate sector remains in a downward phase, but measures taken by various cities to stabilize the market have led to a narrowing year-on-year decline in national commodity housing sales [1] - The trend of stabilizing and recovering the real estate market is ongoing [1] Group 3: Company Performance - The company reported a revenue of RMB 197.8 billion and an operating profit of RMB 10.3 billion for Q3 2025 [2] - For the first nine months of 2025, the company achieved a revenue of RMB 1,030 billion and an operating profit of RMB 131.5 billion [2] Group 4: Land Acquisition - In Q3 2025, the company acquired 9 new land parcels in five cities in mainland China, with a total construction area of 1.49 million square meters [1] - The total land price amounted to RMB 60.5 billion, with an equity land price of RMB 36.52 billion [1]

将由深圳泰运通向深业泰然及深圳地铁置业提供的贷款合共本金金额分别为人民币12.9亿元及人民币 12.4亿元。贷款融资的期限应为自第一批贷款发放日起计36个月。在此期间，贷款方可根据借款方的资 金要求，以一批或多批的方式发放贷款。贷款按单利固定年利率0.05%计息，于整个贷款期间保持不 变。 深圳控股(00604)发布公告，于2025年10月24日，深圳泰运通(公司间接非全资附属公司)与其股东(即深 业泰然及深圳地铁置业)订立贷款协议，据此，深圳泰运通同意按照深业泰然及深圳地铁置业于深圳泰 运通所持股权比例，并根据相同的条款及条件向彼等提供贷款。 深圳泰运通为主要从事发展及建设位于深圳的一个住宅项目的项目公司。该项目已完成且深圳泰运通已 于项目中产生盈余现金。由于深圳泰运通并无重大资本需求，通过向其股东按各自股权比例提供贷款 (所有贷款均以深圳泰运通内部闲置资源拨付)，深圳泰运通能够更有效地利用盈余现金，并让其股东(包 括作为股东之一的集团)从其回笼现金。因此，订约方在厘定贷款协议项下的利率时已参考现行市场储 蓄利率，且贷款协议的条款乃由订约方经公平磋商后协定。 ...

TARGET确证性临床研究是针对三尖瓣反流的患者的一项前瞻性、多中心、单臂研究，该研究在欧洲 (主要于德国、义大利、西班牙)、英国及加拿大30余家心血管中心进行，共计招募150名患者。 启明医疗-B(02500)发布公告，近日，公司经导管介入瓣膜置换创新系统Cardiovalve欧洲确证性临床研 究顺利完成全部150例经导管三尖瓣置换(TTVR)患者入组。这是Cardiovalve在三尖瓣反流治疗领域的又 一次重大研发进展，标志着其在获得CE MDR的道路上迈出了重要里程碑。 董事会深信，Cardiovalve完成欧洲确证性临床试验全部患者入组，是其上市进程的重大里程碑，也是全 球三尖瓣反流创新疗法的重大进展。凭借公司在全球结构性心脏病领域建立的研发、生产及商业化的优 势，公司将持续积极推进包括Cardiovalve在内的创新产品的全球临床註册开发进程，将有竞争力的产品 早日获批，使得更多患者获益及实现公司的国际化战略。 Cardiovalve是一款自主研发、同时可用于治疗二尖瓣反流和三尖瓣反流的经导管介入置换产品。与同类 产品相比，Cardiovalve经股静脉的入路方式显著提升了治疗安全性，产品最大55m ...

Core Viewpoint - 招银国际 maintains a "Buy" rating for 巨子生物 (02367) with a target price of HKD 58.35, despite a weak online sales performance for 可复美 during the first phase of Double Eleven sales [1] Group 1: Financial Performance - 可复美's online revenue is estimated to decline by 10% year-on-year in 2H25, leading to an overall online revenue growth rate of approximately 5% for the year [1] - 可丽金 is expected to achieve a high growth rate of about 40% in online revenue for the year [1] - The company's revenue growth forecast for 2025 is expected to slow down to 12% [1] - The CAGR for 可复美's revenue growth from 2025E to 2027E has been revised down from 26% to 14.5% due to short-term pressures on online sales [1] Group 2: Product Development - 巨子生物's first injectable recombinant collagen product, recombinant type I α1 collagen lyophilized fiber, has been approved for use in facial dermal tissue filling to correct dynamic wrinkles, including frown lines, forehead lines, and crow's feet [1] - The approval marks the completion of the company's product matrix layout for aesthetic injections, post-surgical recovery (dressing), and functional skincare [1] - The company is progressing with the commercialization of injectable products [1] Group 3: Upcoming Products - The company has two additional injectable collagen products in the approval stage: 1. Injectable recombinant collagen filler for moderate to severe neck wrinkles, prioritized for medical device approval by December 2024 [2] 2. Recombinant collagen implant, submitted for registration as a drug-device combination by August 2025, currently under review [2] - The approval of these products will further enrich the company's aesthetic product matrix, covering a range of anti-aging scenarios from forehead to neck and improving skin texture [2]